Clinical pathology selected abstracts

Prostate cancer is the second most common cancer and the fifth leading cause of cancer-associated mortality among men worldwide. The use of serum prostate-specific antigen (PSA) to screen for prostate cancer is intended to detect the cancer at an early stage to reduce overall and disease-specific mortality. However, evidence that PSA screening for prostate cancer saves lives is somewhat lacking. Furthermore, there is concern about harm from overdiagnosis and complications from diagnosis and treatments for what may be an indolent disease. The U.S. Preventive Services Task Force recently updated its recommendation statement for PSA-based screening, changing it from a grade D recommendation, which advises against PSA-based screening for prostate cancer, to a grade C recommendation, which advocates for an individualized approach to screening. 
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Biotin interference on immunoanalyses

labroots

In this webinar, Marie Piketty recalls that in recent years, several cases of interference caused by Biotin have been reported, concerning doses of thyroid hormones, but also other hormones, and other dosages. Biotin also called Vitamin B7, is a cofactor of several reactions to the carboxylase. Biotin present in multivitamin cocktails, does not present a risk of interference, but the use of Biotin at supraphysiological doses as a product of "beauty" (for hair, nails and skin), or at high doses as treatment in patients with multiple sclerosis can cause interference.
Watch Now

It’s Never Too Late: Improve Clinical Trial Processes with a Unified Platform

Veeva

As scientific innovation has led to new trial designs, modern cloud technologies have enabled the industry to better manage how clinical trials are executed. Newer, more advanced cloud applications now offer unified data and process models, allowing organizations to manage their end-to-end clinical trial process within a single system. Rather than juggling individual point solutions, innovative organizations are using a unified clinical platform for greater efficiency, quality, and speed of execution. Join Veeva and Idorsia to learn how your organization can leverage a unified clinical operating model and drive new levels of efficiency across the entire clinical ecosystem.
Watch Now

Uncovering the Secrets of AAV for Improved Cell and Gene Therapies

We are all keenly aware that viruses can negatively impact our lives, but what about viruses that shape our existence and even improve some of its outcomes? In the past several decades, advances in cell and gene therapies have exploded due to innovations with adeno-associated virus (AAV). Yet, given its small genomic size, the life cycle of AAV is surprisingly complex. Understanding this life cycle will be pivotal to developing new and improved methods of AAV vector manufacture that can meet the industry’s increasing needs. Interestingly, in nature, AAV co-exists with adenovirus, with the latter providing help during the AAV life cycle. Thus, taking cues from nature, investigators have developed a novel tetracycline enhanced self-silencing adenoviral (TESSA) helper system that allows for contaminant-free AAV manufacture.
Watch Now

Integration of On-line HPLC as a PAT Tool for CQA Monitoring and Control in Bioprocessing

High-performance liquid chromatography (HPLC) is a proven tool for the analysis of critical process parameters (CPP) and critical quality attributes (CQA) of biotherapeutics. Historically, HPLC has been performed off-line – a process that can take days or weeks to complete.
Watch Now

Spotlight

resources